Ginkgo Bioworks Inc. (DNA)
Ginkgo Bioworks Statistics
Share Statistics
Ginkgo Bioworks has 58.03M shares outstanding. The number of shares has increased by -97.51% in one year.
| Shares Outstanding | 58.03M |
| Shares Change (YoY) | -97.51% |
| Shares Change (QoQ) | -4.25% |
| Owned by Institutions (%) | 0.04% |
| Shares Floating | 46.85M |
| Failed to Deliver (FTD) Shares | 13.85K |
| FTD / Avg. Volume | 0.84% |
Short Selling Information
The latest short interest is 7.83M, so 13.62% of the outstanding shares have been sold short.
| Short Interest | 7.83M |
| Short % of Shares Out | 13.62% |
| Short % of Float | 16.87% |
| Short Ratio (days to cover) | 5.41 |
Valuation Ratios
The PE ratio is -0.93 and the forward PE ratio is -1.54. Ginkgo Bioworks's PEG ratio is 0.02.
| PE Ratio | -0.93 |
| Forward PE | -1.54 |
| PS Ratio | 2.24 |
| Forward PS | 0.9 |
| PB Ratio | 0.71 |
| P/FCF Ratio | -1.33 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Ginkgo Bioworks.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.62, with a Debt / Equity ratio of 0.61.
| Current Ratio | 5.62 |
| Quick Ratio | 5.62 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | -0.91 |
| Debt / FCF | -1.15 |
| Interest Coverage | -5954.86 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $272.23K |
| Profits Per Employee | $-655.91K |
| Employee Count | 834 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -479K |
| Effective Tax Rate | 0.09% |
Stock Price Statistics
The stock price has increased by -86.24% in the last 52 weeks. The beta is 1.24, so Ginkgo Bioworks's price volatility has been higher than the market average.
| Beta | 1.24 |
| 52-Week Price Change | -86.24% |
| 50-Day Moving Average | 9.96 |
| 200-Day Moving Average | 9.81 |
| Relative Strength Index (RSI) | 34.41 |
| Average Volume (20 Days) | 1.65M |
Income Statement
In the last 12 months, Ginkgo Bioworks had revenue of 227.04M and earned -547.03M in profits. Earnings per share was -10.54.
| Revenue | 227.04M |
| Gross Profit | 188.49M |
| Operating Income | -559.76M |
| Net Income | -547.03M |
| EBITDA | -484.39M |
| EBIT | -547.6M |
| Earnings Per Share (EPS) | -10.54 |
Balance Sheet
The company has 561.57M in cash and 438.77M in debt, giving a net cash position of 122.81M.
| Cash & Cash Equivalents | 561.57M |
| Total Debt | 438.77M |
| Net Cash | 122.81M |
| Retained Earnings | -5.84B |
| Total Assets | 1.38B |
| Working Capital | 495.48M |
Cash Flow
In the last 12 months, operating cash flow was -319.58M and capital expenditures -62.54M, giving a free cash flow of -382.13M.
| Operating Cash Flow | -319.58M |
| Capital Expenditures | -62.54M |
| Free Cash Flow | -382.13M |
| FCF Per Share | -7.36 |
Margins
Gross margin is 83.02%, with operating and profit margins of -246.54% and -240.94%.
| Gross Margin | 83.02% |
| Operating Margin | -246.54% |
| Pretax Margin | -241.15% |
| Profit Margin | -240.94% |
| EBITDA Margin | -213.35% |
| EBIT Margin | -246.54% |
| FCF Margin | -168.31% |
Dividends & Yields
DNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DNA is $10, which is 66.7% higher than the current price. The consensus rating is "Sell".
| Price Target | $10 |
| Price Target Difference | 66.7% |
| Analyst Consensus | Sell |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Aug 20, 2024. It was a backward split with a ratio of 1:40.
| Last Split Date | Aug 20, 2024 |
| Split Type | backward |
| Split Ratio | 1:40 |
Scores
| Altman Z-Score | -6.34 |
| Piotroski F-Score | 3 |